James Hardie and Others Face Class Action Lawsuits
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2h ago
0mins
Source: Globenewswire
- James Hardie Lawsuit: A class action lawsuit against James Hardie alleges that from May to August 2025, the company failed to disclose misleading sales information, potentially impacting investor perceptions and stock price.
- Avantor Legal Issues: Avantor faces a class action lawsuit for the period from March 2024 to October 2025, claiming it did not disclose its competitive positioning was weaker than publicly represented, which may lead to investor losses.
- Synopsys Allegations: Synopsys is implicated in a class action lawsuit from December 2024 to September 2025 for failing to disclose that its focus on AI customers was negatively affecting its Design IP business economics, potentially harming financial results.
- CarMax Growth Prospects Questioned: CarMax is facing a class action lawsuit for the period from June to September 2025, accused of overstating growth prospects based on temporary customer behavior due to tariff speculation, which may result in investor losses.
AVTR
$11.205+Infinity%1D
Analyst Views on AVTR
Wall Street analysts forecast AVTR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVTR is 13.86 USD with a low forecast of 12.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
4 Buy
6 Hold
0 Sell
Moderate Buy
Current: 11.240
Low
12.00
Averages
13.86
High
17.00
Current: 11.240
Low
12.00
Averages
13.86
High
17.00
About AVTR
Avantor, Inc. is a life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. The Company’s segments include Laboratory Solutions and Bioscience Production. Within its segments, it sells materials and consumables, equipment and instrumentation and services and specialty procurement to customers in the biopharma and healthcare, education and government and advanced technologies and applied materials industries. Materials and consumables include ultra-high purity chemicals and reagents, lab products and supplies, highly specialized formulated silicone materials, customized excipients, and others. Equipment and instrumentation include filtration systems, virus inactivation systems, incubators, analytical instruments, and others. Services and specialty procurement include onsite lab and production, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
